Lasmiditan

Lasmiditan

Systematic (IUPAC) name
2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide
Clinical data
Legal status	Investigational
Routes of administration	Oral, intravenous
Identifiers
ATC code	none
PubChem	CID: 11610526
IUPHAR/BPS	3928
ChemSpider	9785281 N
UNII	760I9WM792 Y
Chemical data
Formula	C19H18F3N3O2
Molecular mass	377.36 g/mol
SMILES CN3CCC(CC3)C(=O)c(n2)cccc2NC(=O)c1c(F)cc(F)cc1F
InChI InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27) N Key:XEDHVZKDSYZQBF-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Lasmiditan (codenamed COL-144) is an investigational drug for the treatment of acute migraine. It was discovered by Eli Lilly and Company and is being developed by CoLucid Pharmaceuticals. Phase II clinical trial for dose finding purposes were completed in 2007 for an intravenous and in early 2010 for an oral application form.

Mechanism of action

Lasmiditan is a serotonin receptor agonist that, like the unsuccessful LY-334,370, selectively binds to the 5-HT_1F receptor subtype. A number of triptans have been shown to act on this subtype as well, but only after their affinity for 5-HT_1B and 5-HT_1D has been made responsible for their anti-migraine activity. The lack of affinity for these receptors might result in fewer side-effects related to vasoconstriction compared to triptans. A 1998 review has found such side-effects to rarely occur in patients taking triptans, but they are contraindicated for patients with ischaemic heart disease, Raynaud's phenomenon or after a myocardial infarction.